Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 457

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 457
---
 Ph.D. in Biology from The Johns Hopkins University. We believe that Dr. Hwang is well -qualifiedto serve as a director of our company based on his familiarity with Profusa’s business, his experience in the life science industry, and his educational background. Non-Employee Directors Joan Braddi— Ms. Braddi has served as a member of Profusa’s board of directors since December 2015. Ms. Braddi has served in a number of positions at Alphabet Inc. (previously Google, Inc.), a technology company, since May 1999, most recently as Vice President, Partnerships. Ms. Braddi received her B.S. in Business Administration from San Jose State University. Qianye Karen Liu, Ph.D.— Dr. Liu has served as a member of Profusa’s board of directors since December 2015. Dr. Liu has been active in healthcare venture investing since 2005. She is a founding partner of 3E Bioventures Capital, a life science focused VC firm which actively invests in innovative therapeutics as well as cross -disciplinaryhealth tech innovations, which was formed in 2015. Prior to a career in investment, Dr. Liu had a successful Internet start -upexperience and had also worked as a consultant at McKinsey & Company. Dr. Liu currently serves on the boards of directors of 3E BioPartners Ltd., 3E Bioventure Partners, LLC, and Beijing 3E Bioventures Investment Management Co.Ltd. Dr. Liu received a Ph.D. in Immunology from Harvard University, Master of Medical Sciences degree from Harvard Medical School, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB — Chungkong Graduate School of Business in China. Siu Wai Ng— Mr. Ng has served as a member of Profusa’s board of directors since April 2018. Mr. Ng has more than 14 years of industry experience, and has been the Head of Healthcare in the Private Equity Department at VMS Group, an asset management firm, since April 2017 and a Managing Director since March 2018. He has also served as an Investment Partner of Panacea Venture Management Company Ltd, a healthcare focused venture capital firm, since July 2021. Prior to joining VMS Group, Mr. Ng was the lead analyst for the China Healthcare Equity Research from September 2015 to April 2016 and an associate then vice president of the healthcare investment